Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Skingenix, Inc.
Study ID
NCT01297400
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Burns

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Investigational Drug, MW-III — DRUG
    Topical application, twice a day
  • Silvadene® Cream 1% [Silver Sulfadiazine] — DRUG
    Topical application, twice a day

Study Details

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

Key Dates

Start date
Mar 11, 2022
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Investigational Drug, MW-III
    Investigational Drug, MW-III
  • Active Comparator: Standard of care
    Silvadene® Cream 1% \[Silver Sulfadiazine\]

Primary Outcome Measure

Time to healing (≥95% re-epithelialization) of the partial thickness target burn. [ Time Frame: 28 days Treatment Period ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Valleywise Health Medical CenterPhoenixArizona85008-
University of CA Davis Medical CenterSacramentoCalifornia95817-
MedStar Washington Hospital CenterWashington D.C.District of Columbia20010-
University of Iowa Health CareIowa CityIowa52242-

Find similar trials in Phoenix, AZ

By research site
Valleywise Health Medical Center· Phoenix, AZUniversity of CA Davis Medical Center· Sacramento, CAMedStar Washington Hospital Center· Washington D.C., DCUniversity of Iowa Health Care· Iowa City, IA

Related Studies